A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), today announced the Scottish Medicines Consortium (SMC) approval of LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration ...

Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with wet AMD is a significant milestone for our company and a testament to our commitment to improving patient outcomes,” ...

ISELIN, N.J., June 10, 2025(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medi ...

LAS VEGAS, NEVADA / ACCESS Newswire / June 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) (“Avant” or the “Company”), and ...

Experts have issued an urgent warning about a symptom that can come to light from taking drugs such as Mounjaro and Ozempic.

Despite the hard work and dedication of hundreds of local grassroots organizations across the country to deliver student ...